Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC) trastuzumab ...

B ERLIN -- The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) delivered impressive results in ...

In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of ...

Trastuzumab rezetecan significantly improves progression-free survival in HER2-positive breast cancer, outperforming standard treatments in a pivotal trial.

Two phase 3 trials suggest that the antibody drug conjugate led to significantly improved outcomes in both the neoadjuvant ...

In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of ...

Hutchmed China reported preclinical data on Thurdsay, showing strong anti-tumour activity for its novel cancer therapy ...

Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about ...

Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced it has entered into a research ...

The first iteration of HER2-targeted drugs showed limited activity in bladder cancer, but the rise of antibody-drug ...

More positive data has been presented at the ESMO Congress on Enhertu (trastuzumab deruxtecan), a specifically engineered ...

Chinese biotech Kelun-Biotech (HKEX: 6990) has gained approval from the National Medical Products Administration for ...